Network Insights Methodology Get Access

Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 10.0 NORMAL Primary: Spectral Shift

$60B+ revenue (Copenhagen) manufactures diabetes, obesity, and hormone replacement therapies. GLP-1 agonist portfolio (Ozempic, Wegovy) drove 2025 growth amid obesity treatment demand surge.

Active M&A and strategic deal activity; recent signal mentions 'game changer' deal but specific details require full article review
-0.48
PSI Score
10.0
Momentum
1%
Confidence
11
Connections
Connected Entities
FDA China United States India Eli Lilly Canada OpenAI CEO Bloomberg Netflix Investing.com
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-07 2026-05-07 11 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.316
Narrative Drift
0.000
Spectral Shift
420.548
Sentiment-Momentum Divergence
0.000
Source Concentration
0.380
Network Analysis
11 Degree Centrality
Centrality History
2026-04-07 2026-05-07 11 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 13 NEW
China 9 NEW
United States 9 NEW
India 8 NEW
Eli Lilly 7 NEW
Canada 6 NEW
OpenAI 4 NEW
CEO 2 NEW
Bloomberg 2 NEW
Netflix 2 NEW
Investing.com 2 NEW
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-07 ← Intelligence Network